http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108344830-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8818 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-88 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-88 |
| filingDate | 2017-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108344830-B |
| titleOfInvention | Urine sample combined marker for diagnosing prostate cancer and detection kit |
| abstract | The present invention relates to the novel use of the small molecule metabolites acetylleucine, propionyl carnitine, butyryl carnitine, kynurenic acid, xanthosine, 5-hydroxy-L-tryptophan, p-cresol sulfate and tryptophan in a urine sample as combined markers for the preparation of a kit for diagnosing prostate cancer patients in a subject. The invention also relates to a kit for detecting a prostate cancer patient in a subject, wherein the subject is judged whether to be a prostate cancer patient by detecting the relative concentration of each of the combined markers in a urine sample from a male subject, calculating the combined marker variables based on a binary logistic regression equation and determining the cut-off value. The combined use of the small molecule metabolites can be applied to the auxiliary diagnosis of the prostate cancer, in particular to the prostate cancer in the clinical 'diagnosis gray zone'. |
| priorityDate | 2017-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 118.